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Hepoxilins are lipid signalling molecules derived from arachidonic acid through the 12-
lipoxygenase pathway. These trans-epoxy hydroxy eicosanoids play a role in a variety of 
physiological processes, including inflammation, neurotransmission and formation of skin 
barrier function. Mammalian hepoxilin hydrolase - partly purified from rat liver - has earlier 
been reported to degrade hepoxilins to trioxilins. Here, we report that hepoxilin hydrolysis in 
liver is mainly catalysed by soluble epoxide hydrolase (sEH). (i) Purified mammalian sEH 
hydrolyses hepoxilin A3 and B3 with a Vmax of 0.4 – 2.5 μmol/mg/min, (ii) the highly 
selective sEH inhibitors N-adamantyl-N’-cyclohexyl urea (ACU) and 12-(3-adamantan-1-yl-
ureido) dodecanoic acid (AUDA) greatly reduced hepoxilin hydrolysis in mouse liver 
preparations; (iii) hepoxilin hydrolase activity was abolished in liver preparations from sEH-/-  
mice and (iv) liver homogenates of sEH-/- mice show elevated basal level of hepoxilins but 
lowered levels of trioxilins compared to WT animals. We conclude that sEH is identical to 
previously reported hepoxilin hydrolase. This is of particular physiological relevance because 
sEH is emerging as a novel drug target, due to its major role in the hydrolysis of important 
lipid signalling molecules such as epoxyeicosatrienoic acids (EETs). sEH inhibitors might 








Supplementary key words: soluble epoxide hydrolase, hepoxilin hydrolase, lipid 
metabolism, hepoxilin, 12-LOX.  
 at SM
AC Consortium














Epoxide hydrolases (EC 3.3.2.7-11) catalyse the hydrolysis of oxiranes to the 
corresponding vicinal diols. To date a number of mammalian epoxide hydrolases are 
characterized that play diverse roles in the organism (1).  
The soluble epoxide hydrolase (sEH, EC 3.1.3.76; EC 3.3.2.10) is a bifunctional, 
homodimeric enzyme composed of an epoxide hydrolase (EH) and a lipid phosphatase in each 
of its subunits (2-4). The sEH is abundantly expressed throughout the organism (5, 6) and 
accepts a broad range of substrates (7, 8), in particular endogenous epoxides derived from 
unsaturated fatty acids such as epoxyeicosatrienoic acids (EETs) (9). The organism utilises 
these lipid epoxides as important signalling molecules which regulate a variety of 
physiological functions. EETs were identified as endothelium derived hyperpolarizing factors 
(EDHF) (10) acting on vascular smooth muscle cells leading to hyperpolarization and 
vasodilation (11, 12). Since then several experimental hypertensive models confirmed a role 
for EETs in blood pressure regulation and end organ protection (13, 14). EETs further have 
antiinflammatory and antinociceptive properties (15-17) and finally seem to promote cell 
proliferation, migration and angiogenesis (18-20).  
The metabolism of these lipid epoxides by sEH to the corresponding diols is generally 
considered a deactivation process. For this reason the sEH is a promising target for the 
treatment of hypertension, inflammatory diseases, pain, diabetes and stroke (16, 21-25). A 
number of sEH inhibitors (sEHI) have been developed (26, 27) for therapeutic applications. 
Yet, the sEH also serves some function in xenobiotic metabolism by accepting certain trans-
substituted epoxides, which are very poor substrates for microsomal epoxide hydrolase 
(mEH) (28, 29). 
Other epoxide hydrolases with rather narrow substrate selectivity have been identified in 
mammals. Of those, Hepoxilin A3 epoxide hydrolase (Hepoxilin hydrolase, EC 3.3.2.7) was 
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partly purified from rat liver cytosol and identified as the main hydrolase of the endogenous 
lipid hepoxilin A3. The authors further discriminated hepoxilin hydrolase from other EHs due 
to its size (53 kDa) and substrates preference for hepoxilin A3, compared to leukotriene or 
styrene oxide (30). To date, the enzyme is only incompletely characterized and no structural 
or sequence information is available.  
Most enzymatic derived endogenous lipid epoxides are of cis-configuration, but also some 
trans-substitutes lipid epoxides are formed within the organism, such as the inflammatory 
mediator leukotriene A4. The trans-epoxy hydroxy eicosanoids hepoxilin A3 and B3 (HxA3 
and HxB3) are formed from arachidonic acid through the 12-lipoxygenase pathway (figure 1) 
in various organs like liver, brain, lung, pancreas and skin (9, 31). They can be transformed to 
the corresponding trihydroxy metabolites (trioxilins, Trx) or glutathione conjugates (32). 
Early studies showed an hepoxilin mediated increased insulin release from pancreatic islets 
(33). In the brain hepoxilins modulate synaptic neurotransmission and neuronal excitability - 
mostly through stimulation of intracellular calcium release or increased calcium influx into 
the cell (34-37). Hepoxilin are considered pro-inflammatory because increased hepoxilins and 
trioxilin levels have been found in psoriatic lesions (38) and hepoxilin A3 was shown to 
regulate neutrophil migration in response to inflammation (39, 40). Several reports suggest an 
involvement of these lipid mediators in epidermal differentiation and skin barrier function 
(41). Interestingly, mutations in the hepoxilin generating 12R-LOX pathway in the skin are 
associated with a congenital form of ichthyosis (42-46). A hepoxilin receptor has not been 
identified, but several reports (34, 47-49) support its existence.  
   Here, we report that 12S-LOX derived hepoxilin A3 and B3 (HxA3 and HxB3), are 
efficiently converted to the corresponding trihydroxy metabolites (trioxilins) by soluble 
epoxide hydrolases (sEH). Our results suggest a biological relevance of sEH - rather than 
hepoxilin hydrolase - in hepoxilin metabolism, which opens a new branch in the numerous 
physiological functions of sEH.  
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Enzyme Assays. Human full length sEH containing an N-terminal Strep-Tag and rat sEH 
containing an N-terminal His-Tag were cloned, recombinantly expressed in E.coli and 
purified as described previously (3). Epoxide hydrolase activity was measured using 8(R,S)-
Hydroxy-11S,12S-epoxyeicosa-5Z,9E,14Z-trienoic acid (HxA3) and 10(R,S)-Hydroxy-
11S,12S-epoxyeicosa-5Z,8Z,14Z-trienoic acid (HxB3) as substrates by determining the 
formation of the corresponding diols 8(R,S)-Hydroxy-11,12-dihydroxyeicosa-5Z,9E,14Z-
trienoic acid (TxA3) and 10(R,S)-Hydroxy-11,12-dihydroxyeicosa-5Z,8Z,14Z-trienoic acid 
(TxB3). Typically, 5-50 ng purified sEH or 10 - 100 µg organ extracts were incubated with 
various concentrations HxA3 and HxB3 ranging from 0.1-30 µM with or without inhibitors in 
50 mM Tris HCl, 50 mM NaCl, 2 % glycerol, pH 7.4 in a final volume of 50 µl for 10 min at 
37°C. The reaction was stopped by addition of 2 volumes of methanol and samples were 
pelleted for 5 min at 13.000 rpm prior to LC-MS/MS analysis. Substrate turnover was 
determined using internal HxA3 and HxB3 standards. EH activity against epoxyeicosatrienoic 
acids (EETs) was performed as described previously (50). Kinetic constants were calculated 
by kinetic modelling based on the equation V = E x CS/(CS+Km) (with V = % turnover of 
Vmax, E = total amount of enzyme, CS = substrate concentration, and Km = Michaelis Menten 
constant). Variations were calculated from 4-5 independent experiments using freshly 
prepared enzyme preparations.  
Lipid substrates were purchased from Biomol except for TxA3 and TxB3, which were 
synthesized biochemically using purified soluble epoxide hydrolase. One µg HxA3 or HxB3 
were turned over to the corresponding diol using 200 ng soluble epoxide hydrolase in 50 mM 
Tris HCl, 50 mM NaCl, 2 % glycerol, pH 7.4 in a final volume of 500 µl for 30 min at 37°C. 
The reaction products were extracted trice with 2 volumes of ethyl acetate, dried under a 
stream of nitrogen and reconstituted in methanol. 
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LC-MS/MS analysis. Separation of analytes was performed on an Agilent eclipse XDB-
C18 reverse phase column (4.6 x 150 mm, 5 μm pore size) with a corresponding opti-gard 
pre-column using an Agilent 1100 liquid chromatography system. The mobile phase consisted 
of (A) 0.1% formic acid and (B) acetonitrile containing 0.1% formic acid at a flow rate of 400 
μl/min using an injection volume of 20 μl. Starting conditions of 70% buffer B were 
maintained for 2 min, followed by a linear gradient from 70 to 100% B within 7 min. An 
isocratic flow of 100% B was held for 1.5 min and finally the column was re-equilibrated for 
2 min with 70% B. The HPLC system was coupled to a 4000 QTRAP hybrid quadrupole 
linear ion trap mass spectrometer (Applied Biosystems) equipped with a TurboV source and 
electrospray (ESI) interface. Analytes were recorded using multiple reaction monitoring in 
negative mode (-MRM) using the following source specific parameters: IS -4500V, TEM 
450°C, curtain gas (CUR = 30), nebulizer gas (GS1 = 50), heater gas (GS2 = 70) and collision 
gas (CAD = 10). The compound specific parameters for the different substrates (as specified 
in supplemental material) were determined by direct infusion of standard solutions (100-300 
ng/ml) in methanol at a flow rate of 10µl/min using the quantitative optimization function of  
the Analyst software 1.4.2. Samples were quantified by determining the peak AUC with the 
quantification function of the Analyst software 1.4.2 using the transitions as specified in 
supplemental material. The background noise was assessed by analysing blank samples and 
standard curves were generated using blank samples spiked with a series of control lipids 
ranging from 1-1000 ng/ml. For HxA3, HxB3, TxA3 and TxB3 the limit of detection (LOD) 
ranged from 4 to 20 pg and the limit of quantification (LOQ) from 15-65 pg, corresponding to 
a signal-to-noise ratio of 3 and 10, respectively.   
 
Organ extracts. C57BL/6 mice were obtained from the Institute of Laboratory Animal 
Sciences University of Zurich and C57BL/6 sEH-/- mice (51) were kindly provided by Dr. F.J. 
Gonzales (NIH, Bethesda, MD, USA). 6-10 week old male mice were sacrificed by cervical 
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dislocation, and livers were excised and homogenized in ice-cold phosphate buffered saline, 
pH 7.4. All subsequent steps were performed at 4°C. Cytosolic and microsomal fractions were 
prepared by ultracentrifugation of the 9000 x g supernatant of the liver homogenates at 
100.000 x g for 45 min.  
 
Lipid extracts. Lipids were extracted from liver homogenates by addition of ethanol to a 
final concentration of 25%, followed by solid phase extraction on C18 Bond Elut SPE 
columns (Varian, Palo Alto, CA, USA). Extracts were applied to the SPE columns 
preconditioned with 2 ml acetonitrile and 2 ml ddH2O. Columns were washed with 1 ml 
ddH2O and evaporated to dryness. Lipids were eluted with 3 x 600 μl ethylacetate, dried 
under a stream of nitrogen, dissolved in acetonitrile, and pelleted for 2 min at 13.000 rpm 
prior to LC-MS/MS analysis as described above. In some cases liver homogenates were 
treated with 30 μM arachidonic acid at 37 °C for 30 min and lipids were isolated by solid 
phase extraction as described above.  
 
Western Blot. Protein samples in Laemmli buffer were subjected to SDS-polyacrylamide 
gel electrophoresis and semi-dry blotting following standard procedures. Blots were incubated 
with polyclonal sEH rabbit antiserum for 2 hours (dilution of 1:1000) in Tris-buffered saline 
containing 0.5% Tween-20. An alkaline phosphatase conjugated anti-rabbit antibody (Sigma 
Aldrich) was applied at a dilution of 1:30000 followed by colorimetric detection using BCIP 






















Soluble epoxide hydrolase efficiently turns over hepoxilin A3 and B3. Human and rat 
sEH were cloned, recombinantly expressed in E.coli and purified to homogeneity using 
affinity chromatography as described previously (3). To determine the effect of purified 
recombinant rat or human sEH on hepoxilin metabolism we used LC-MS/MS analysis 
followed by kinetic evaluation. Human or rat sEH was incubated with various concentrations 
of HxA3 and HxB3 with or without inhibitors and samples were analysed by LC-MS/MS. 
HxA3 is efficiently hydrolysed by purified rat soluble epoxide hydrolase with a Vmax of 1.7 
µmol/mg/min, a Km of 5 µM and a catalytic efficiency of 4.5 x 105 as shown in figure 2. Both 
HxA3 and HxB3 are substrates for purified rat sEH and also human sEH (figure 2) and a 
summary of the kinetic parameters is presented in table 1.  
 
Hepoxilin hydrolase activity is linked to sEH presence. To evaluate the physiological 
contribution of sEH to hepoxilin metabolism, we separated mouse liver cytosolic fractions 
using gel permeation chromatographie and tested each elution fraction for the metabolism of 
HxA3, 14,15-EET and 5,6-EET. Each fraction was further assayed for the presence of sEH by 
western blot analysis (figure 3). The hepoxilin hydrolase and sEH activities show 100% co-
elution from the column. Moreover, the fraction with the highest hepoxilin hydrolase activity 
also contains the highest amount of sEH (figure 3, lower panel).  
 
Hepoxilin turnover is inhibited by sEH but not mEH inhibitors. To characterise the 
physiological contribution of sEH to hepoxilin metabolism, we used a selection of epoxide 
hydrolase inhibitors. The hepoxilin turnover by purified sEH was effectively inhibited by 
sEHIs as shown in figure 4. Hepoxilin metabolism in liver protein extracts from WT animals 
was inhibited by ACU and AUDA but not the mEH inhibitor valpromide, as shown in figure 
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5. In addition, ACU inhibited hepoxilin metabolism by purified rat sEH and liver cytosolic 
preparations with an IC50 value of approximately 1 nM (data not shown), which is in line with 
previously reported data (52). In microsomal preparations of sEH WT mice hepoxilin 
turnover amounted to 30% compared to the cytosolic fraction. Western blot analysis of 
microsomal and cytosolic liver preparations confirmed the presence of sEH protein in both 
liver fractions, although to significantly lower amount in microsomes (data not shown). 
Furthermore, purified microsomal epoxide hydrolase which is highly abundant in the liver 
does not show any activity against hepoxilins (data not shown). 
 
sEH is responsible for hepoxilin metabolism. To investigate the quantitative contribution 
of sEH to hepoxilin turnover we incubated protein extracts isolated from livers of sEH WT 
and sEH-/- mice with HxA3 and HxB3. Hepoxilin turnover to trioxilins was greatly abolished 
in sEH-/- mice compared to the WT mice (figure 6). Specifically, in both cytosolic and 
microsomal liver preparations of sEH-/- mice, the activity towards HxA3 and HxB3 was greatly 
reduced compared to the WT mice. Again, the activity towards hepoxilins in liver microsomal 
preparations of WT animals is explained by the presence of some sEH, while no sEH protein 
was detectable in the sEH-/- mice by immunoblotting (data not shown).  
 
Hepoxilin/trioxilin contents of livers of WT and sEH-/- mice in vivo. Lipids were 
extracted from liver organ preparations of sEH WT and sEH-/- mice with or without pre-
treatment with arachidonic acid followed by LC-MS/MS analysis of the lipids. Liver 
homogenates of sEH-/- mice show a significantly elevated basal level of hepoxilin B3 but 
lowered levels of trioxilins compared to the WT animals (figure 7a), where trioxilins are 
readily formed. After arachidonic acid treatment of organ extract the synthesis of hepoxilin 
precursors is greatly induced (40fold) and the accumulation of hepoxilins in liver 
homogenates from sEH-/- mice is even more pronounced (figure 7b).   
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Here we report for the first time that trans-hydroxy-epoxy lipids, in particular the 
endogenous 12S-LOX derived lipid mediators HxA3 and HxB3 are excellent substrates for 
mammalian sEH and converted to the corresponding trioxilins. 12R-LOX derived hepoxilins 
which are specifically generated in skin are most likely preferred sEH substrates, although 
they have not been tested to date. sEH metabolises hepoxilins with a catalytic efficiency 
which is within the range of turnover of its previously identified physiological substrates 
epoxyeicosatrienoic acids (EETs) which are among the best endogenous substrates for sEH. 
The activity of mammalian sEH against EETs lies in the range of 1-20 µmol/mg/min. We do 
not see a negative cooperativity with both hepoxilins, like it has been suggested for the EET 
turnover by sEH (50). Human sEH turns over hepoxilins less efficiently (by a factor of three) 
than rat sEH. This has been seen for other substrates and might be explained by a 
compensatory effect due to the lower expression level of sEH in rat liver compared to human 
liver. HxA3 is a better substrate for mammalian sEH than HxB3. The hydroxy group 
positioned directly next to the epoxide might pose a sterical hindrance leading to less efficient 
turnover by sEH.  
The sEH turns over hepoxilins orders of magnitudes more efficiently than the previously 
reported hepoxilin hydrolase that displayed a specific activity of 0.2 nmol/mg/min. Hepoxilin 
hydrolase was partly purified from rat liver and suggested to be distinct from other 
mammalian EHs (mEH, sEH, Leukotriene A4 Hydrolase) by its molecular weight as well as 
substrate and inhibitor spectrum. However, hepoxilin hydrolase is still only incompletely 
characterized and the amino acid sequence is not reported to date. The purification scheme 
used for the isolation of hepoxilin hydrolase (30) is quiet similar to the procedure used for the 
isolation of rat liver sEH (53). We assume that the hepoxilin hydrolase activity in the enzyme 
preparation published previously is due to an invisible contamination by sEH. The assignment 
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of the enzymatic activity to an incorrect polypeptide might be due to the obviously low 
abundance of sEH in livers of untreated rats, which would also explain the striking activity 
difference between the two enzymes.  
These results suggested a physiological role of sEH in hepoxilin metabolism. Analysis of 
mouse liver cytosol by gel permeation chromatography followed by activity measurements 
against HxA3, 14,15-EET (an excellent sEH substrate) and 5,6-EET (a rather poor sEH 
substrate) and western blot revealed that the hepoxilin hydrolase activity is linked to sEH 
presence, showing a perfect match. The double peak in the activity profile can be explained 
by the presence of monomeric and dimeric sEH in liver cytosol. These results suggested that 
mammalian sEH – rather than hepoxilin hydrolase - is the key enzyme responsible for 
hepoxilin metabolism in mouse liver. 
To strengthen our hypothesis we analysed liver extracts from sEH WT and sEH-/- mice. 
Hepoxilin turnover was greatly abolished compared to the WT animals. The activity against 
hepoxilins found in the liver microsomal preparation of WT animals can be explained by the 
presence of sEH due to its partial peroxisomal localisation in liver (54, 55), which we 
confirmed by western blot analysis.  
Only sEHIs but not mEHIs quantitatively inhibited hepoxilin turnover in cytosolic as well 
as microsomal liver preparations of WT animals. mEH shows a substrate preference for 
bulky, cis-substituted epoxides compared to the sEH, which accepts both cis- and trans-
substituted epoxides. Indeed, we have shown that purified microsomal epoxide hydrolase does 
not turnover hepoxilins. In addition, ACU inhibited hepoxilin metabolism by purified rat sEH 
as well as liver cytosolic preparations with an IC50 value of approximately 1 nM. These 
results are further supported by the LC-MS/MS analysis of lipid fractions prepared from 
organs of sEH WT and sEH-/- animals. The liver homogenates of sEH-/- mice show elevated 
basal levels of hepoxilins, particularly HxB3, while trioxilins levels are significantly decreased 
compared to the WT animals (figure 7a). The pre-treatment of organ extracts with arachidonic 
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acid (AA) presumably leads to a strong production of hepoxilin precursors such as 12HPETE. 
In this case, both HxA3 and HxB3 significantly accumulate in the livers of   sEH-/- animals and 
only a slow turnover to trioxilins is detected (figure 7b). An AA pre-treatment better reflects 
the actual enzyme capacity of the organ analysed, while in the basal state compensatory 
mechanisms of lipid metabolism might be of importance.  
Quit unexpected were the large amounts of particularly HxB3 in the livers of sEH-/- mice 
while HxA3 did not accumulated to that extent. HxA3 has been shown to be a substrate for 
glutathione-S-transferases, and the glutathione conjugated metabolite maintains biologic 
activity (32, 37). Due to the high expression level of GSTs in the liver, one would expect a 
lack of hepoxilin accumulation, which is only seen for the HxA3 regioisomer (figure 7). 
Therefore glutathione conjugation of HxB3 does not seem to be an important pathway in the 
liver. Note that the glutathione derivative of HxB3 has not been detected in vivo to date. In 
contrast, HxA3 seem to be preferentially glutathionylated in livers of sEH-/- animals, which 
might also be the case in other organs, when the epoxide hydrolysis pathway is blocked.  
Taken together our results strongly suggest that mammalian sEH is the key enzyme 
responsible for hepoxilin metabolism and indeed identical to previously reported hepoxilin 
hydrolase. Other mammalian epoxide hydrolase contribute – if at all – only partly to this 
metabolic pathway, depending on the tissue analysed.  
Our inhibitory analyses using sEHI clearly show a complete block of hepoxilin hydrolysis 
in the liver. Therefore possible undesirable effects of sEH inhibitors, which are in 
development for a number of applications, should be considered. Lipid signalling pathways 
other then the mostly targeted EET pathways might be affected, with – to our knowledge – 
unknown consequences. This is even more important as EETs and hepoxilins seem to have 
somewhat opposing effects. While the action of EETs are generally considered anti-
inflammatory (15-17), hepoxilins instead are suspected to have pro-inflammatory effects. In 
psoriatic lesions elevated levels of hepoxilins and trioxilins have been detected (38). 
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Furthermore, hepoxilin A3 has recently been identified as pathogen elicited epithelial 
chemoattractant (PEEC). HxA3 leads to neutrophil migration across epithelial barriers in 
response to mucosal inflammation in the intestine or lung (39, 40). An inhibition of sEH 
might therefore cause enhanced release of hepoxilins at inflammatory sites. Such a 
deregulation might trigger pathophysiological effect of inflammation seen for example in 
inflammatory bowel disease, cystic fibrosis or chronic obstructive pulmonary disease of the 
lung.   
In conclusion, hepoxilins are excellent substrates for mammalian sEH in vitro and in vivo. 
Our findings suggest that sEH is identical to liver hepoxilin hydrolase and plays an important 
role in the physiological regulation of hepoxilins, with important implications in particular for 
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Tables and Figures 
 
Figure 1: Biosynthesis and metabolism of hepoxilins. Hepoxilins are synthesised from 
arachidonic acid by the action of 12S-lipoxygenase (12S-LOX) and epidermis-type 
lipoxygenase 3 (eLOX-3), leading to the regioisomers hepoxilin A3 and B3. The hepoxilins 
are turned over by sEH to the corresponding trihydroxy metabolites TrxA3 and B3. (Note that 
in the skin a specific 12R-LOX generates hepoxilins with R-configuration. This pathway 
plays a role in epidermal differentiation and skin barrier function.) 
 
Figure 2: Kinetic analysis of hepoxilin turnover by sEH. Human and rat sEH were cloned, 
recombinantly expressed in E.coli and purified as described above. Purified enzymes were 
incubated with various concentrations of substrate and samples were analysed by LC-MS/MS. 
Substrate turnover was determined using internal HxA3 and HxB3 standards and the 
quantification function of the Analyst software 4.2.1. Kinetic constants were calculated by 
simulation of the Michaelis Menten kinetic as described in the experimental section.  
 
Figure 3: Gel Permeation Chromatographie. 5 mg mouse liver cytosol was separated on a 
SE-1000 gel permeation column (Amersham biosciences) in phosphate buffered saline, pH 
7.4. Each elution fraction was assayed for the metabolism of HxA3, 14,15-EET and 5,6-EET 
(600 nM) as described in the experimental section. Each fraction was further analysed for the 
presence of sEH protein by western blot (lower panel). 
 
Figure 4: Inhibition of sEH. Rat and human sEH were incubated with 3 µM HxA3 and HxB3 
in the presence of sEH selective inhibitors (2 µM ACU, 2 µM AUDA) and samples were 
analysed by LC-MS/MS as described in the experimental section. Bars represent the amount 
of hepoxilin formed by sEH in the presence of inhibitors compared to the control without 
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inhibitor. The inserted representations show the structures of the sEH inhibitors ACU (1-
Adamantyl-3-cyclohexylurea) and AUDA (12-(3-adamantan-1-yl-ureido)-dodecanoic acid).  
 
Figure 5: Inhibition of hepoxilin metabolism. Protein extracts from liver (cytosolic and 
microsomal preparations) of WT mice were incubated with 3 µM HxA3 and HxB3 in the 
presence of inhibitors (2 µM ACU, AUDA, 2 mM valpromide), and samples were analysed 
by LC-MS/MS. The representations show the fraction (%) of substrate turnover compared to 
the cytosolic preparation of WT animals which is adjusted to 100% turnover.  Error bars 
indicate the standard deviation. Unpaired, one-sided Student’s t-tests were performed on each 
set of inhibited versus non inhibited samples. Two stars indicate a significant statistical 
difference with a p-value < 0.01.   
 
Figure 6: Hepoxilin metabolism by sEH in WT and sEH-/- mice. Protein extracts (50 ug) 
from liver (cytosolic and microsomal preparations) of sEH-/- and WT mice were incubated 
with 3 µM HxA3 and HxB3, and samples were analysed by LC-MS/MS. The representations 
show the fraction (%) of substrate turnover compared to the cytosolic preparation of WT 
animals which is adjusted to 100% turnover. Error bars indicate the standard deviation. 
Unpaired, one-sided Student’s t-tests were performed on each set of samples from WT versus 
KO animals. Two stars indicate a significant statistical difference with a p-value < 0.01.   
 
Figure 7: Lipid extracts. a) Levels of hepoxilins and trioxilins in liver extracts of WT and 
sEH-/- mice.  Liver samples of sEH WT and sEH-/- animals were homogenized, adjusted to a 
final concentration of 20% ethanol and lipids were isolated by solid phase extraction. b) 
Levels of hepoxilins and trioxilins in liver extracts of WT and sEH-/- mice upon stimulation 
with exogenous arachidonic acid. Liver samples of sEH WT and sEH-/- animals were 
homogenized and treated with 30 µM arachidonic acid for 30 min. Samples were adjusted to a 
 at SM
AC Consortium












final concentration of 20% ethanol and lipids were isolated by solid phase extraction. Samples 
were analysed for hepoxilin metabolism by LC-MS/MS. The values are presented in pmol 
lipid per g tissue. Error bars indicate the standard deviation. Unpaired, one-sided Student’s t-
tests were performed on each set of samples from WT versus KO animals. Two stars indicate 




































Table 1. Summary of kinetic parameters for hepoxilin turnover by sEH.  
 
 sEH substrate Vmax  Km  kcat  kcat/Km 
  nmol/mg/min µM s-1 M-1s-1 
 
 rsEH HxA3 1739 ± 539 4.6 ± 2.3 1.88 ± 0.58 4.5 x 105 ± 1.6x105 
 rsEH HxB3 550 ± 261 14.7 ± 5.3 0.60 ± 0.28 5.1 x 104± 1.4 x 104 
 hsEH HxA3 385 ± 95 7.3 ± 3.3 0.42 ± 0.10 5.8 x 104± 9.5 x 103 
 hsEH HxB3 95± 43 10.8 ± 3.4 0.10 ± 0.05 1.2 x 104± 8.4 x 103 
 
Kinetic constants were calculated by simulation of the Michaelis Menten kinetic as described 
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